RxDoctor Payments Data

Mark Brus, MD

Internal Medicine · Sarasota, FLNPI 1922097948

Payments from drug & device makers

$13,168in general payments, 2019–2025

Across 781 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$902
  • GSK$860
  • Amgen$779
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,145100%
  • Education$90%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)77$1,376
Pfizer80$1,326
Lilly USA, LLC75$1,200
Novo Nordisk58$902
GSK80$860
Amgen(2 entities)54$779
Bayer33$775
Merck42$678
Sumitomo Pharma America, Inc.26$612
AstraZeneca27$583
Boehringer Ingelheim36$574
Exact Sciences14$347
Novartis15$205
IBSA Pharma Inc.13$202
Sunovion Pharmaceuticals Inc.12$197
Dexcom, Inc.9$177
Boston Scientific4$172
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$159
Sanofi-aventis U.S. LLC8$159
Johnson & Johnson10$154
Astellas Pharma US Inc8$116
Otsuka America Pharmaceutical, Inc.6$108
Biohaven Pharmaceutical Holding Company Ltd.7$103
Biohaven Pharmaceuticals, Inc.4$95
Abbott5$95
Idorsia Pharmaceuticals US Inc5$92
Hologic Sales And Service, LLC3$74
Shionogi Inc4$69
Xeris Pharmaceuticals, Inc.3$66
Takeda Pharmaceuticals U.S.A., Inc.4$65
Cranial Technologies, Inc3$61
Daiichi Sankyo Inc.3$58
Amarin Pharma, Inc.3$52
Acadia Pharmaceuticals Inc2$49
Ironwood Pharmaceuticals, Inc2$44
Antares Pharma, Inc.3$43
Lundbeck LLC3$41
Lucid Diagnostics Inc.2$38
Radius Health, Inc.2$32
Phathom Pharmaceuticals, Inc.2$32
E.r. Squibb & Sons, L.L.C.2$30
Harmony Biosciences LLC2$30
Shire North American Group Inc2$29
Paratek Pharmaceuticals, Inc.2$29
Bausch Health US, LLC1$25
Hikma Pharmaceuticals USA1$24
Shield Therapeutics Inc1$21
Regeneron Healthcare Solutions, Inc.1$21
Aimmune Therapeutics, Inc.1$19
GE HealthCare1$17
Almatica Pharma LLC1$17
Mannkind Corporation1$17
Genentech USA, Inc.1$16
Halozyme Inc1$16
Nevro Corp.1$15
Eisai Inc.1$13
Optos, Inc.1$13
Kowa Pharmaceuticals America, Inc.1$12
Pharming Healthcare, Inc.1$12
Teva Pharmaceuticals USA, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,168 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$286,018
Medicare patients
946
Services billed
3,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban186$203,284
OzempicSemaglutide161$174,768
MounjaroTirzepatide129$144,540
JardianceEmpagliflozin72$119,467
NuplazidPimavanserin Tartrate12$51,925
FarxigaDapagliflozin Propanediol39$49,191
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$47,872
XareltoRivaroxaban48$39,035
CreonLipase/Protease/Amylase12$30,172
LinzessLinaclotide12$18,941
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$16,504
GemtesaVibegron13$16,097
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$15,535
MyrbetriqMirabegron16$15,138
TrulicityDulaglutide11$12,332

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$1,326$210,353274 claims
Novo NordiskOzempic$902$174,768161 claims
Lilly USA, LLCMounjaro, Trulicity$1,200$156,872140 claims
Boehringer IngelheimJardiance, Spiriva Respimat$574$126,87986 claims
GSKTrelegy Ellipta, Anoro Ellipta$860$63,40788 claims
AbbVieCreon, Linzess, Synthroid, Lumigan$1,376$59,416112 claims
Acadia Pharmaceuticals IncNuplazid$49$51,92512 claims
AstraZenecaFarxiga$583$49,19139 claims
Johnson & JohnsonXarelto$154$39,03548 claims
Sumitomo Pharma America, Inc.Gemtesa$612$16,09713 claims
Astellas Pharma US IncMyrbetriq$116$15,13816 claims
NovartisEntresto$205$10,49119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →